San Diego, CA -- (SBWIRE) -- 11/21/2016 -- An investigation on behalf of investors of Intersect ENT Inc (NASDAQ:XENT) shares over potential securities laws violations in connection certain financial statements was announced.

Investors who purchased shares of Intersect ENT Inc (NASDAQ:XENT), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Intersect ENT Inc (NASDAQ:XENT) concerning whether certain statements regarding Intersect ENT Inc's business, its prospects and its operations were materially false and misleading at the time they were made.

Commercial stage drug-device company Intersect ENT Inc conducted its initial public offering in July 2014. Shares of Intersect ENT Inc (NASDAQ:XENT) grew from $12.30 per share in August 2014 to as high as $32.44 per share in July 2015.

Menlo Park, CA based Intersect ENT Inc reported that its annual Total Revenue rose from 38.59 per million in 2014 to $61.59 million in 2015 while its Net Loss increased from $18.36 million in 2014 to $26.63 million in 2015.

On November 2, 2016, Intersect ENT Inc reported its third quarter 2016 results and updated its 2016 outlook.

Shares of Intersect ENT Inc (NASDAQ:XENT) declined on November 2, 2016 to as low as $7.65 per share.

On November 18, 2016, NASDAQ:XENT shares closed at $11.95 per share.

Those who purchased shares of Intersect ENT Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com